Next-generation sequencing technologies have emerged as a promising technology in a variety of fields, including genomics, epigenomics, and transcriptomics. These technologies play an important role in understanding cell organization and functionality. Unlike data from earlier technologies (e.g., microarrays), data from next-generation sequencing technologies are highly replicable with little technical variation. One application of next-generation sequencing technologies is RNA-Sequencing (RNA-Seq). It is used for detecting differential gene expression between different biological conditions. While statistical methods for detecting differential expression in RNA-Seq data exist, one serious limitation to these methods is the absence of biological replication. At present, the high cost of next-generation sequencing technologies imposes a serious restriction on the number of biological replicates. We present a simple parametric hierarchical Bayesian model for detecting differential expression in data from unreplicated RNA-Seq experiments. The model extends naturally to multiple treatment groups and any number of biological replicates. We illustrate the application of this model through simulation studies and compare our approach to existing methods for detecting differential expression such as, Fisher's Exact Test.
Introduction
Next-generation sequencing technologies have emerged as a promising approach for exploring the cell organization and functionality, and are used in a variety of fields, including genomics, epigenomics, and transcriptomics (Hayden, 2009 , Metzker, 2009 , Ng et al., 2010 , and Roach et al., 2010 . Unlike data from earlier technologies such as microarrays, data from next-generation sequencing technologies are highly replicable with little technical variation (Marioni et al., 2008) .
Data from next-generation sequencing technologies are in the form of discrete gene counts that represent the relative amount of expression of each gene in the genome. When this technology is used to detect differential gene expression between different biological conditions, it is referred to as RNA-Sequencing (RNA-Seq). Similar to other high-throughput data, RNA-Seq data are high-dimensional data, and typically involve limit number of samples (that is, number of individuals analyzed) compared to the number of predictors (that is, genes); a problem known as "big p small n" or "curse of dimensionality".
Research in high dimensional data first gained momentum with the analysis of microarray data.
It has lead to significant advancements in the theory of multiple hypotheses testing (Efron et al., 2001 ), variable selection (Zou and Hastie, 2005) , and the use of false discovery rates (FDR) for multiple testing problems (Benjamini and Hochberg, 1995, Storey, 2003) . In order to model such data Efron (2010) recommends approaches such as empirical Bayesian methods that take advantage of information-borrowing across genes to compensate for limited availability of samples. Also, there are Bayesian approaches (Baldi and Long, 2001, Ibrahim et al., 2002 ) and penalized-likelihood based approaches (Tibshirani et al., 2004, Ma and Huang, 2007) that take advantage of information-borrowing amongst genes. Many of these ideas have been applied to RNA-Seq data to determine differential gene expression with the central themes of calculating gene-wise test statistics, shrinking them towards a common value, and using FDR adjusted pvalues for the modified test statistics to determine differentially expressed genes. Interestingly, RNA-Seq data pose two main non-trivial problems that do not arise when dealing with microarray data. First, due to the discrete nature of the data there are no equivalents of a t-test or an F-test (Casella and Berger, 2001) ; rather, the distribution of the test statistic is determined by the asymptotic likelihood distribution approximations (Anders and Huber, 2010 , Robinson and Smyth, 2007 . Second, due to overdispersion, small counts, and zero inflation which are very common in RNA-Seq data, the assumption of a Poisson distribution on gene counts may not be justified (Vêncio et al., 2004 , Thygesen, 2006 , Hardcastle and Kelly, 2010 . Currently, RNASeq data represent a subsample of gene counts that are obtained from the original population of genes in the sample assessed by next-generation sequencing technologies. The total number of genes in the sample assessed by next-generation sequencing technologies is called the library size of the sample. The library size may vary depending on the sample. The effect of differences due to library size is discussed in Robinson and Oshlack (2010) .
One of the important issues in RNA-Seq experiments is determining differentially expressed genes. Accurate modeling of gene abundance is crucial for determining differential gene expression. Gene abundance is defined as the population mean from which the gene count is sampled (i.e., the sample assessed by the next-generation sequencing technology). The gene counts are modeled as a Poisson random variable, and are assumed to be independent of the size of the population (i.e., the total number of gene counts in the sample assessed by the nextgeneration sequencing technology). Presently, very little attention has been paid to identifying differentially expressed genes in unreplicated experiments mainly because of lack of reliable statistical inference in unreplicated experiments and reliable asymptotic theory. But many unreplicated experiments are conducted by biologists for the purpose of surveying an organism, for preliminary analysis, or because of the high cost of next-generation sequencing technologies.
Here we present a simple parametric hierarchical Bayesian model for detecting differential gene expression in data from unreplicated RNA-Seq experiments. Our method borrows information across genes to compensate for the missing information about variation within a treatment group.
The model determines the differential expression of each gene through their posterior probability distribution, and extends naturally to multiple treatment groups and any number of biological replicates. Simulation studies are employed to compare the results of our approach to currently used methods for detecting differential expression in unreplicated RNA-Seq data such as, Fisher's Exact Test (Agresti, 2002) .
Hierarchical Bayesian Modeling Framework
We use a hierarchical Bayesian model (Gelman et al., 2003, Gelman and Hill, 2007) ∑ . The total number of samples, S, is chosen large enough so that the MCMC chains mix well, and we obtain 95% CI for determining differential gene expression with reasonable coverage. The mixing of MCMC chains is tested in JAGS through the Gelman-Rubin diagnostic statistic and trace plots (Gelman and Rubin, 1992) We can identify all the differentially expressed genes in the RNA-Seq data using equation 2.7. If 0 does not belong to CI g , then we conclude that gene g is differentially expressed with 95%
probability. Otherwise, we conclude that the gene is not differentially expressed.
Simulations and Results
We rely on simulated data to illustrate an application of hierarchical Bayesian modeling (equation 2.2) for determining differential gene expression from unreplicated RNA-Seq data. We also compare the results of the hierarchical model with Fisher's Exact for detecting differential gene expression in unreplicated experiments.
Simulation Setting
Typically, the total number of genes involved in any transcriptome experiment involves at least thousands of genes. We assume that the total number of genes sampled is 1000, and that there are two treatment levels. Treatment 1 is assumed to be the baseline case. (Gentleman et al., 2004) , edgeR (Section 12, . This is different from the modeling assumption in equation 2.2, which assumes gt θ to be log-normal. units is arbitrary; if the difference is increased, it is easier to estimate the differentially expressed genes accurately.
Results
We fit the hierarchical Bayesian model (equation 2.2 -2.6) on the simulated RNA-Seq data using R and JAGS. We sampled 2000 draws from the posterior distributions for 4 parallel MCMC chains. The mixing was proper and confirmed through Gelman-Rubin diagnostic statistic and trace plots. Figures 1 and 2 summarize the results of simulation. Figure 1 illustrates the density plot for the estimated and true differential gene expression parameters for all the genes pooled together. Since there are two subsets of genes, one differentially expressed and the other not-differentially expressed, we expect a bimodal density estimate. Also, since the means of differentially expressed genes differ from the non-differentially expressed genes by 100 untis, after normalizing for library effects we expect the bimodal density estimate peaks around 0 and an estimated mean around the true value (0.0002); it is more prominent for the true density plot.
The estimated and true densities are both bimodal with closely matching peaks. The last subset contains the genes with 100 lowest posterior medians. We randomly sample five genes from these ten subsets and plot the 95% CIs for these genes on the y-axis and assign colors according to the subset membership of the genes. In Figure 2 , the y-axis represents the 95% CIs and the x-axis contains the corresponding gene names. Furthermore, we order the genes according to their posterior medians to make the pattern clearer. From this we observe that the CIs for all the sampled genes from the first subset do not contain 0, and conclude they are differentially expressed. The CI for genes from remaining subsets includes 0, hence a majority of genes in these subsets are not differentially expressed. We also detect false positives, that is, genes that are not differentially expressed, but are declared differentially expressed. Specifically, The hierarchical Bayesian approach (equation 2.2 -2.6) detects 152 differentially expressed genes among the 1000 simulated gene profiles. Specifically, we detect the differentially expressed genes with 100% accuracy and detect 52 false positives. Since these results are based on the 95% credible intervals of differential expression, we expect to arrive at a wrong conclusion for approximately 50 genes. Therefore, the hierarchical Bayesian method performs well, even in unreplicated experiments, given the prior assumptions are valid.
Comparisons of hierarchical Bayesian model with Fisher's Exact Test
We employed the Fisher's Exact Test (FET) to detect differentially expressed genes, and to compare to the results of hierarchical Bayesian modeling. We chose FET because it is the most commonly used method for estimating differential gene expression in unreplicated RNA-Seq data (Marioni et al., 2008) .. We used R (R Development Core Team, 2011) to perform gene-wise testing and to obtain p-values for all the genes. The p-values were adjusted using the False Discover Rate (FDR) multiple comparison procedure (Benjamini and Hochberg, 1995) . FET detects 89 differentially expressed genes at a FDR of 5%. Out of these, only one is a false positive and the remaining 88 genes are true positives, (i.e., they are differentially expressed), and these 89 genes are a subset of the genes detected as differentially expressed by the hierarchical Bayesian modeling approach (Section 3.2). By comparison, FET is conservative when compared to the results of the hierarchical Bayesian model.
In our simulation setting the difference between the means of differentially and non-differentially expressed genes is considerably large by practical standards. Because the gene abundances of the differentially and non-differentially expressed genes will not be well-separated in real data (i.e., a mixture of distribution issue), the results of FET in real data will be even more conservative. In this setting the real benefit of hierarchical Bayesian approach can be seen, since it gains power from the information borrowing among the genes in a treatment. The inference can be further strengthened by borrowing information across treatments among similar genes. This said, the hierarchical Bayesian approach is not without its limitations. Since the results of the hierarchical Bayesian model are based on strong prior assumptions that may not be true in general, validation of such assumptions is required. Obviously, in cases where the prior assumptions can be justified, hierarchical Bayesian will be more powerful. However, for filtering genes for further exploration with good accuracy in unreplicated experiments, we suggest including genes that are declared significant by both FET and hierarchical Bayesian model.
Discussion
Statistically, the lack of replication imposes a serious restriction on the detection of differentially expressed genes based on classical approaches. The hierarchical Bayesian model (equation 2.2-2.6) provides an option for detecting differentially expressed genes in unreplicated RNA-Seq experiments. It is more powerful than classical approaches such as Fisher's Exact Test if the prior assumptions are justified. This said, we must remark that this method is based on many, possibly strong, assumptions. First, the assumption of gamma prior distribution imposed on the mean parameters of gene counts may not be justified, and second, there might be other factors affecting the gene counts that are not included in the second level of hierarchy in equation 2.2.
Despite these drawbacks, the model is an effective method of modeling information borrowing and improving inference about differential gene expression that is not possible using the classical approaches. The hierarchical Bayesian method of estimating differentially expressed can be extended to the detection of differentially expressed genes for increasing numbers of replicates and treatment group which will lead to better estimation of within group variation, and thus better overall inference about differential expression of genes. We have implemented the methods discussed here in JAGS and R. The code can be used to analyze any RNA-Seq data using hierarchical Bayesian model (equation 2.2 -2.6) with minor modifications.
